All In Biotech

NDA 206333 · Abbvie

Kybella

Deoxycholic Acid · Subcutaneous · Cytolytic Agent

Novel

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Apr 29, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

205

52 Phase 3, 21 recruiting

FAERS reports

2,334

189 serious, 10 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 11, 2026.

KYBELLA ® is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. Limitations of U se KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region, and such use is not recommended [see Warnings and Precautions ( 5.5 )]. KYBELLA is a cytolytic drug indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. ( 1 ) Limit ation s of Use KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region, and such use is not recommended. ( 1 , 5.5 )

Mechanism: KYBELLA is a cytolytic drug, which when injected into submental fat - in patients with moderate to severe convexity or fullness associated with submental fat - physically destroys the cell membrane causing lysis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • KYBELLA · DEOXYCHOLIC ACID 20MG/2ML (10MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Deoxycholic Acid" as an intervention, any sponsor and status, largest first.

All 205 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective327
  • injection site swelling305
  • off label use287
  • swelling262
  • injection site pain191
  • facial paresis130
  • injection site nodule123
  • nerve injury115
  • hypoaesthesia110
  • injection site mass104
  • injection site induration86
  • contusion85

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20142
201539
2016354
2017212
2018392
2019314
2020219
2021219
2022203
2023208
202471
202573
202627

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 140 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.